Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

For Merck, the drug that concerns investors is Keytruda. The blockbuster cancer drug faces patent expiration in 2028.

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Amid fears of an "extremely high level of violent protests," the Brampton Triveni Mandir and Community Centre has cancelled a Life Certificate Event.

Phuket is pulling out all the stops in a monumental bid to raise a whopping 290 million baht. The cause? Building a cutting-edge cancer care centre at Vachira Phuket Hospital. This essential ...